Chana Weinstock

1.5k total citations
44 papers, 842 citations indexed

About

Chana Weinstock is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Chana Weinstock has authored 44 papers receiving a total of 842 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Chana Weinstock's work include Renal cell carcinoma treatment (14 papers), Bladder and Urothelial Cancer Treatments (11 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Chana Weinstock is often cited by papers focused on Renal cell carcinoma treatment (14 papers), Bladder and Urothelial Cancer Treatments (11 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Chana Weinstock collaborates with scholars based in United States, Belgium and Australia. Chana Weinstock's co-authors include Richard Pazdur, Shenghui Tang, Daniel L. Suzman, Kirsten B. Goldberg, Julia A. Beaver, Amna Ibrahim, Marc R. Theoret, Rajeshwari Sridhara, V. Ellen Maher and Sean Khozin and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Chana Weinstock

39 papers receiving 830 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chana Weinstock United States 12 558 301 140 127 119 44 842
Capucine Baldini France 16 686 1.2× 280 0.9× 140 1.0× 140 1.1× 103 0.9× 89 964
T. Barnes Canada 12 610 1.1× 256 0.9× 141 1.0× 173 1.4× 157 1.3× 28 988
Pedro Nazareth Aguiar Brazil 13 584 1.0× 428 1.4× 84 0.6× 98 0.8× 120 1.0× 73 861
Taizo Hirata Japan 12 555 1.0× 285 0.9× 49 0.3× 153 1.2× 145 1.2× 36 808
G. Schubert-Fritschle Germany 16 485 0.9× 217 0.7× 168 1.2× 164 1.3× 185 1.6× 58 847
Robert H. El-Maraghi Canada 10 622 1.1× 256 0.9× 123 0.9× 121 1.0× 289 2.4× 22 848
Anastasios Dimou United States 16 481 0.9× 311 1.0× 67 0.5× 201 1.6× 115 1.0× 67 800
Yongrui Bai China 14 278 0.5× 244 0.8× 191 1.4× 181 1.4× 143 1.2× 49 739
Qi Lin China 18 410 0.7× 274 0.9× 169 1.2× 251 2.0× 204 1.7× 67 927
M. Puglisi Italy 16 539 1.0× 408 1.4× 91 0.7× 257 2.0× 68 0.6× 38 998

Countries citing papers authored by Chana Weinstock

Since Specialization
Citations

This map shows the geographic impact of Chana Weinstock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chana Weinstock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chana Weinstock more than expected).

Fields of papers citing papers by Chana Weinstock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chana Weinstock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chana Weinstock. The network helps show where Chana Weinstock may publish in the future.

Co-authorship network of co-authors of Chana Weinstock

This figure shows the co-authorship network connecting the top 25 collaborators of Chana Weinstock. A scholar is included among the top collaborators of Chana Weinstock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chana Weinstock. Chana Weinstock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Chang, Elaine, Chi Song, Haley Gittleman, et al.. (2024). A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma. Clinical Cancer Research. 30(15). 3282–3286. 5 indexed citations
4.
Brave, Michael H., William F. Maguire, Chana Weinstock, et al.. (2024). FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(21). 4815–4821. 14 indexed citations
5.
6.
Fallah, Jaleh, Brian L. Heiss, Hee‐Koung Joeng, et al.. (2024). FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research. 30(22). 5003–5008. 9 indexed citations
7.
Maguire, William F., Daniel Lee, Chana Weinstock, et al.. (2024). FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(10). 2011–2016. 13 indexed citations
8.
Chang, Elaine, Haley Gittleman, Erik Bloomquist, et al.. (2023). FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.. Journal of Clinical Oncology. 41(16_suppl). e16532–e16532.
9.
Lee, Daniel, Haley Gittleman, Chana Weinstock, et al.. (2023). A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma. European Urology. 84(4). 373–378. 8 indexed citations
10.
Brave, Michael H., Chana Weinstock, Jamie R. Brewer, et al.. (2020). An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 26(18). 4717–4722. 20 indexed citations
11.
12.
Anscher, Mitchell S., Shaily Arora, Chana Weinstock, et al.. (2020). Impact of radiotherapy on risk of adverse events in patients receiving immunotherapy: A U.S. Food and Drug Administration pooled analysis.. Journal of Clinical Oncology. 38(15_suppl). 3018–3018. 3 indexed citations
13.
Fiero, Mallorie H., Madeline Pe, Chana Weinstock, et al.. (2020). Demystifying the estimand framework: a case study using patient-reported outcomes in oncology. The Lancet Oncology. 21(10). e488–e494. 31 indexed citations
14.
Weinstock, Chana, V. Ellen Maher, Laura L. Fernandes, et al.. (2019). An FDA analysis of the association between adverse events and outcome in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) antibody.. Journal of Clinical Oncology. 37(15_suppl). 4549–4549. 1 indexed citations
15.
Raju, G. K., Harpreet Singh, Chana Weinstock, et al.. (2019). Using a Benefit–Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell Carcinoma. Clinical Pharmacology & Therapeutics. 107(3). 495–506. 4 indexed citations
16.
Weinstock, Chana, Sean Khozin, Daniel L. Suzman, et al.. (2017). U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(16). 4534–4539. 115 indexed citations
17.
Weinstock, Chana, C Campassi, Olga Goloubeva, et al.. (2015). Breast magnetic resonance imaging (MRI) surveillance in breast cancer survivors. SpringerPlus. 4(1). 43 indexed citations
18.
Weinstock, Chana, et al.. (2012). Outcomes of Surveillance for Contralateral Breast Cancer in Patients Less than Age 60 at the Time of Initial Diagnosis. Current Oncology. 19(3). 160–164. 7 indexed citations
19.
Weinstock, Chana. (1984). Psychophysiological aspects of cancer. Medical Hypotheses. 15(4). 369–383. 1 indexed citations
20.
Weinstock, Chana. (1983). Psychosomatic elements in 18 consecutive cancer regressions positively not due to somatic therapy.. PubMed. 30(4). 151–5. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Capucine Baldini Breakdown of academic impact, for papers by T. Barnes Breakdown of academic impact, for papers by Pedro Nazareth Aguiar Breakdown of academic impact, for papers by Taizo Hirata Breakdown of academic impact, for papers by G. Schubert-Fritschle Breakdown of academic impact, for papers by Robert H. El-Maraghi Breakdown of academic impact, for papers by Anastasios Dimou Breakdown of academic impact, for papers by Yongrui Bai Breakdown of academic impact, for papers by Qi Lin Breakdown of academic impact, for papers by M. Puglisi
Rankless by CCL
2026